A phase 1 study of crizotinib has shown it to have a clinical marked effect in the treatment of advanced non–small-cell lung cancer (NSCLC) patients with ALK-EML4 rearrangement and other ALK gene rearrangements, with an objective response rate (ORR) of 60.8% and a progression-free survival (PFS) time of 9.7 months [7]. Here, ALK is linked to non-small cell lung carcinoma.